Insights

Why the Painchek (ASX:PCK) share price is edging higher today

The PainChek (ASX: PCK) share price rose today against the market as the company announced its half-year report. We take a closer look.
The post Why the Painchek (ASX:PCK) share price is edging higher today appeared first on The Motley Fool Australia. –

A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies

The PainChek Ltd (ASX: PCK) share price was among the few ASX shares that stayed in the green today, closing up 2.56% at 8 cents.

The share price increase came off the back of the company half-year report announced to the market yesterday. Let’s take a look.

Why did the Painchek share price rise today?

Shares in the small-cap rose as revenue jumped 40% to $2.08 million for the half-year ending 30 December 2020.

However, this does not fully represent how the company performed in the period. Looking deeper into the results, we can see that revenue from continuing operations fell 30% to $127,000. The majority of the group’s revenue was made up of research and development (R&D) and government grants.

As such, the company reported a net loss from operations for the half-year of $1.35 million.

PainChek continued to deliver sales growth in Australian residential aged care (RAC). Sales growth in the period resulted in total global licenses covering 71,318 beds, a 123% growth year on year (YoY). Furthermore, domestic sales reflected more than 30% of the Australian RAC.

Moreover, the company now has 884 aged care clients, growing 133% on the previous corresponding period. Forward-looking revenue equates to more than $3 million in annualised recurring revenue.

Looking ahead

PainChek aims to further develop its platform for use in new and larger healthcare market segments. The company said this was core to its business growth over the next 12 months.

In addition, the company has a number of products pending regulatory clearance. PainChek’s business strategy includes the release of an app for assessing pain in young children.

Having recently completed the app development and clinical validation work, the company is projecting Australian (TGA) and European (CE) mark regulatory clearances in the second quarter of the calendar year 2021.

Promisingly, its children’s app serves a potentially larger market than the adult app with a large hospital market and home care market opportunity.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Painchek (ASX:PCK) share price is edging higher today appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!